Supplier News: Cambrex, Lonza, Forcyte Bio & More
By

The latest from CDMOs, CMOs, and suppliers featuring Cambrex, Snapdragon Chemistry, Sai Life Sciences, Lonza, Forcyte Bio, ILC Dover, Upperton Bio, National Resilience and Eurofins CDMO Alphora.  

Chemicals/Chemical API Manufacturing 
* Cambrex Completes Acquisition of Snapdragon Chemistry   
* Sai Life Sciences Opens High-Potency API Mfg Facility 
* Eurofins CDMO Alphora Expands API Development Lab 
Biologics Manufacturing 
* Resilience Partners with Investment Firm for New Biomanufacturing Facility in United Arab Emirates 
* Forcyte Bio Opens Viral-Vector, Cell-Therapy Mfg Facility 
* ILC Dover Opens Raw Materials, Dry Repack Facility 
Formulation Development/Drug Product Manufacturing 
* Lonza Completes Expansion of Solid-Form Services Facility
* Upperton Pharma Breaks Ground on New Clinical Drug-Product Mfg Facility 


Chemicals/Chemical API Manufacturing 

Cambrex Completes Acquisition of Snapdragon Chemistry 
Cambrex has completed its acquisition of Snapdragon Chemistry, a Waltham, Massachusetts-based provider of flow-chemistry process design and technology development services. The acquisition was announced in November 2022 

Snapdragon specializes in active pharmaceutical ingredient batch and continuous flow process development. Snapdragon has more than 70 employees and recently opened its second facility, a new 51,000-square-foot facility that expanded the company’s capacity for supplying clinical intermediates and drug substances. 

Source: Cambrex 


Sai Life Sciences Opens High-Potency API Mfg Facility 
Sai Life Sciences, a Hyderabad, India-headquartered CDMO of intermediates and active pharmaceutical ingredients (APIs) and discovery chemistry services, has opened a new high-potency API (HPAPI) manufacturing facility at its cGMP API manufacturing campus in Bidar, India.  

The new 16,000-square-foot HPAPI facility can handle HPAPIs with less than 1 μg/m3 containment. It also includes the following: a warehouse to store key starting materials, intermediates and finished goods;  a dedicated sampling/dispensing area with isolators with three independent streams to handle commercial-scale batches; reactors to handle multiple unit operations equipped with isolators and split butterfly valves; powder processing and a packing area with isolators; dedicated isolator train for quality control testing, and a deactivation facility. 

Earlier in 2022, the company had opened an HPAPI development facility at its Hyderabad R&D campus. 

Source: Sai Life Sciences 


Eurofins CDMO Alphora Expands API Development Lab 
Eurofins CDMO Alphora, a Mississauga, Ontario, Canada-based CDMO owned by Eurofins, a contract analytical testing company, has relocated and expanded its active pharmaceutical ingredient (API) development laboratories, with a new lab in Sheridan Research Park in Mississauga, Ontario, Canada. 

The 56,000-square-foot building houses the company’s API process R&D activity, solid-state R&D activity, and its analytical services team. The laboratory facility includes the following: 26 fume hoods supporting process R&D; a 50-L scale kilo laboratory equipped with six walk-in fume hoods; cGMP analytical services; high-potency API development laboratories; a new Bruker 400 mHz NMR; and offices for employees and client meetings. 

Source: Eurofins CDMO  


Biologics Manufacturing 

Resilience Partners with Investment Firm for New Biomanufacturing Facility in United Arab Emirates 
National Resilience, a San Diego, California-based CDMO of biologics, and Mubadala Investment Company, an Abu Dhabi, United Arab Emirates (UAE)-based investment firm, have partnered for a new biomanufacturing facility in Abu Dhabi, UAE. 

Under the agreement, Mubadala will establish the new manufacturing facility, which will be operated by Resilience, to manufacture certain biopharmaceutical-related products in the UAE. As part of the collaboration, Resilience has agreed to provide manufacturing, technology, and operational expertise for the Abu Dhabi-based facility and integrate the site as a node within its global network. Additionally, Mubadala will make an equity investment into National Resilience as part of the agreement. 

Source: National Resilience  


Forcyte Bio Opens Viral-Vector, Cell-Therapy Mfg Facility 
Forecyte Bio, a Frederick, Maryland-based CDMO of cell and gene therapies, has opened its new GMP facility for the manufacturing of viral vectors, cell therapies, and plasmid DNA.  

The new facility has 17,000 square feet of space and consists of individual cleanroom suites for plasmid DNA, viral vectors, and cell therapies, as well as laboratory space for process development and quality control testing. The facility is equipped with bioreactors and purification apparatus.  

Source: Forcyte Bio 


ILC Dover Opens Raw Material, Dry Repack Facility 
ILC Dover, a Newark, Delaware-based company focused on single-use products for bio/pharmaceutical processing, has opened a new facility in Lillington, North Carolina, for pre-filled trusted-weight cGMP raw materials for biomanufacturing.  

The new 48,000-square-foot site provides a portfolio of cGMP raw materials and dry repack capabilities across three ISO 7 cleanroom suites. The new capability follows a recent expansion project within Dover’s Durham production facility, which now offers water for injection produced by distillation, a raw material for bio/pharmaceuticals and cell and gene therapies. 

The raw mateials are used primarily for buffer and cell-culture media preparations in biopharmaceutical processing. The company has started to fill and repack dry chemicals in Lillington with additional capabilities coming in early 2023. 
 

Source: ILC Dover 


Formulation Development/Drug Product Manufacturing 

Lonza Completes Expansion of Solid Form Services Facility   
Lonza has completed an expansion of its solid-form services offering for small-molecule drugs at its facility in Bend, Oregon. The expansion became fully operational in the fourth quarter of 2022.  

The expanded facility includes laboratory space, which is primarily being used to support biotech and mid-sized pharma companies in developing early-stage compounds. It can support all aspects of solid form screening and characterization of small-molecule active pharmaceutical ingredients and early crystallization process development.  

The facility is equipped with powder and fume hoods and small-scale crystallization systems. Spectroscopic, thermal and other techniques are available in the new and existing adjacent spaces. This includes the following: Fourier transform infrared spectroscopy; high-performance liquid chromatography; dynamic vapor sorption; thermal gravimetric analysis; differential scanning calorimetry; powder X-ray diffraction; solid-state and liquid nuclear magnetic resonance; gas chromatography; and polarized light microscopy. 

Source: Lonza 


Upperton Pharma Breaks Ground on New Clinical Drug-Product Mfg Facility 
Upperton Pharma Solutions, a Nottingham, UK-based CDMO of drug products, has begun construction of a  new development and GMP manufacturing headquarters in Nottingham, UK.  

The new 50,000-square-foot site will expand the company’s capabilities in terms of manufacturing capacity and scale and will include 10 new GMP manufacturing suites, quality control laboratories, and dedicated analytical and formulation development laboratories with pilot-plant facilities.  

The site will have the capability to handle a range of dosage forms including solids, liquids, semi-solids, nasal and inhaled products to support early formulation development, clinical trial supplies from Phase I to Phase III, and niche-scale commercial manufacture. The GMP facility design, equipment procurement and containment capabilities have been aligned with larger scale process trains to support batch scales of up to 250 kg. 

The facility is expected to be fully operational by the end of 2023 and is expected to create approximately 150 additional full-time jobs by the end of 2024. 

Source: Upperton Pharma Solutions